Genfit SA
PAR:GNFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Raito Kogyo Co Ltd
TSE:1926
|
JP |
|
Brookfield Renewable Partners LP
TSX:BEP.UN
|
BM |
|
T
|
Tanco Holdings Bhd
KLSE:TANCO
|
MY |
Genfit SA
EPS (Diluted)
Genfit SA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genfit SA
PAR:GNFT
|
EPS (Diluted)
-€1
|
CAGR 3-Years
-53%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-10%
|
|
|
Valneva SE
PAR:VLA
|
EPS (Diluted)
€0
|
CAGR 3-Years
18%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-9%
|
|
|
Inventiva SA
PAR:IVA
|
EPS (Diluted)
-€1
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
EPS (Diluted)
$0
|
CAGR 3-Years
34%
|
CAGR 5-Years
19%
|
CAGR 10-Years
0%
|
|
|
DBV Technologies SA
PAR:DBV
|
EPS (Diluted)
-$1
|
CAGR 3-Years
5%
|
CAGR 5-Years
19%
|
CAGR 10-Years
7%
|
|
|
Abivax SA
PAR:ABVX
|
EPS (Diluted)
-€4
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-10%
|
|
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
See Also
What is Genfit SA's EPS (Diluted)?
EPS (Diluted)
-1.7
EUR
Based on the financial report for Dec 31, 2025, Genfit SA's EPS (Diluted) amounts to -1.7 EUR.
What is Genfit SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-10%
The average annual EPS (Diluted) growth rates for Genfit SA have been -53% over the past three years , 8% over the past five years , and -10% over the past ten years .
